Compare IDEXX Laboratories, Inc. (IDXX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Consumer Staples Select Sector SPDR Fund — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× Consumer Staples Select Sector SPDR Fund's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| IDXX | XLP | |
|---|---|---|
Market Cap | $40.43B | $13.50B |
Volume | 692,164 | 14,599,953 |
Sector | Health | — |
52-Week High | $766.68 | $90.00 |
52-Week Low | $504.70 | $75.61 |
Typical Hold Time | 46 Days | 72 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong defensive characteristics amid market volatility, with 100% analyst buy ratings and a forthcoming dividend. Recent news highlights its outperformance versus discretionary sectors and competitive positioning against peers like VDC and IYK.
Outlook remains positive given defensive sector strength and favorable expense ratio, though risks include interest rate sensitivity and consumer spending shifts. The ETF's focus on household staples provides stability, but elevated RSI levels suggest near-term consolidation potential before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
